Comparing two ways to monitor muscle relaxation during anesthesia in people with obesity
Compares two muscle monitoring methods in adults with obesity having weight-loss surgery.
Plain-language title generated from the registry record
Registry title: Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia
Key facts
- Where
- Padova, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with severe obesity who are scheduled for weight-loss (bariatric) surgery under general anesthesia. It compares two ways of monitoring muscle relaxation during surgery.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Pathological obesity: Class II with other health conditions, or Class III. Scheduled for bariatric surgery under general anesthesia.
Main reasons for not taking part
- Severe acute or long-term lung disease (for example asthma, COPD, severe restrictive disease)
- Severe or recent heart disease (for example recent heart attack, inducible ischemia, heart failure)
- End-stage liver or kidney disease
- Intolerance, allergy, or contraindication to the study-related drugs
- No written informed consent
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07283354, who can take part
Where in Italy
- Azienda Ospedale - Università di Padova (Padua University Hospital)Padova, ItalyContact: Michele CarronNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Padova
- Trial code
- NCT07283354
- Record updated
- 15 December 2025
- Original description
The goal of this prospective observational study is to compare two different methods of monitoring muscle relaxation during anesthesia - acceleromyography (AMG) and electromyography (EMG) - in people with obesity who are having bariatric surgery with general anesthesia and the muscle relaxant rocuronium.Read full original descriptionShow less
Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia With Rocuronium: A Prospective Observational Study
The goal of this prospective observational study is to compare two different methods of monitoring muscle relaxation during anesthesia - acceleromyography (AMG) and electromyography (EMG) - in people with obesity who are having bariatric surgery with general anesthesia and the muscle relaxant rocuronium.
The main question is: Which method is more accurate and precise in measuring the Train-of-Four (TOF) ratio during surgery? As part of this comparison, researchers will also note how quickly each method detects recovery of muscle function after the reversal drug sugammadex.
Participants will:
* Receive standard anesthesia care for bariatric surgery, including rocuronium to relax the muscles. * Have two small monitoring devices applied, one to each hand: AMG on one hand, EMG on the other. * Be monitored for muscle function during surgery and after receiving sugammadex to reverse the muscle relaxation.
Researchers will also record how easy each device is to use and whether participants have any breathing problems after surgery.
Inclusion: Adults aged 18-65 years; Pathological obesity (Class II with comorbidities or Class III); Scheduled for bariatric surgery under general anesthesia; Written informed consent obtained.
Exclusion: Severe acute or chronic respiratory disease (e.g., asthma, COPD, severe restrictive disease); Severe acute or recent cardiac disease (e.g., acute or recent myocardial infarction, inducible ischemia, heart failure); End-stage hepatic or renal disease; Intolerance, allergy, or contraindication to study-related drugs; Absence of informed consent.